Stay updated with breaking news from Jon Congleton. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mineralys Therapeutics, Inc. presented final results from the Target-HTN Phase 2 trial of lorundrostat at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, and simultaneously published in the Journal of the American Medical Association (JAMA).
Although U.S. stocks closed higher on Friday, there were a few notable insider trades.
– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure , including an enhanced response in individuals with...
Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six analysts that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have covered the stock […]
29.08.2023 - RADNOR, Pa., Aug. 29, 2023 (GLOBE NEWSWIRE) - Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced ...